Luis Voloch and Noam Solomon (Immunai)

Stan­ford, Park­er In­sti­tute sci­en­tists team up with two young en­gi­neers in $20M AI play with an im­munol­o­gy fo­cus

Al­most a year ago, a group of sci­en­tists at Stan­ford and the Park­er In­sti­tute for Can­cer Im­munother­a­py pub­lished a pa­per in Na­ture Med­i­cine that chal­lenged a com­mon as­sump­tion about where tu­mor fight­ing cells come from: While re­searchers had thought that the role of check­point block­ade was to rein­vig­o­rate T cells al­ready present in the tu­mor, they sug­gest­ed that the vast ma­jor­i­ty ac­tu­al­ly didn’t come from the tu­mor sites at all.

An­su Sat­pa­thy

The find­ing was made pos­si­ble by sin­gle-cell RNA se­quenc­ing tech­nol­o­gy, which cap­tured tens of thou­sands of cells over time and re­vealed that the army of ac­tive T cells could be found in the blood­stream.

Two re­searchers on the team — Stan­ford pathol­o­gy pro­fes­sor An­su Sat­pa­thy and PI­CI se­nior da­ta sci­en­tist Dan­ny Wells — had been ad­vis­ing an AI start­up with a can­cer fo­cus. But with­in a few months, they jumped on board Im­mu­nai as found­ing sci­en­tists and steered it to­ward a slight­ly dif­fer­ent di­rec­tion, one tied close­ly with the T cell work.

By build­ing an end-to-end plat­form from sam­ple pro­cess­ing to data­base as­sem­bly to da­ta min­ing for bi­o­log­i­cal in­sights, Im­mu­nai’s ul­ti­mate goal is to map out the en­tire im­mune sys­tem, co-founder and CEO Noam Solomon told End­points News.

The com­pa­ny is now emerg­ing from stealth with $20 mil­lion in a seed round led by Vi­o­la Group and TLV Part­ners.

Solomon was a post­doc at MIT when his friend and even­tu­al busi­ness part­ner, Luis Voloch, got him ex­cit­ed about tran­si­tion­ing from tech to biotech — or tech­bio as they would call it. Voloch, who cut his teeth in ma­chine learn­ing at Palan­tir, is now the chief tech­nol­o­gy of­fi­cer of Im­mu­nai.

Dan­ny Wells

They were par­tic­u­lar­ly fas­ci­nat­ed with the com­pu­ta­tion­al con­cept of trans­fer learn­ing, which al­lows one to ap­ply knowl­edge in one area (such as au­toim­mune dis­eases) to an­oth­er (such as can­cer im­munother­a­py).

“That’s why it’s im­por­tant for us to un­der­stand the im­mune sys­tem from the top down,” Voloch said. “It’s on­ly when you look at all these things at once that you can re­al­ly un­der­stand the in­ter­play be­tween these dif­fer­ent cell types and the dif­fer­ent func­tions that these cell types have in dif­fer­ent sce­nar­ios.”

For phar­ma part­ners with check­point drugs and cell ther­a­pies in de­vel­op­ment, Im­mu­nai promis­es to an­swer ques­tions about how com­bos might act to­geth­er on dif­fer­ent cells — with an eye for new bio­mark­ers and tar­gets. When it comes to CAR-T and oth­er TCR ther­a­pies, Voloch said, the team can al­so pro­file the drug be­fore in­fu­sion, track­ing per­for­mance by sub­pop­u­la­tion.

“Our first en­deav­or is to un­der­stand mech­a­nisms of the im­mune sys­tem,” Solomon con­clud­ed.

Un­like some of the oth­er AI shops that have popped up in bio­phar­ma, Im­mu­nai is cer­tain it will not step in­to its own drug dis­cov­ery and de­vel­op­ment. Rather, its 30-strong work­force in Tel Aviv, New York and San Fran­cis­co will de­vote all their at­ten­tion to play­ing as­sist in the bio­phar­ma world. Be­yond the ini­tial ap­pli­ca­tions in can­cer, it al­so sees a fu­ture in every­thing from in­fec­tious dis­ease to Alzheimer’s.

“To each dis­ease there is an im­mune com­po­nent,” Solomon added. “Build­ing this wide data­base, this pan-im­mune data­base, we will be able to de­code this com­po­nent.”

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

In the past couple of years, something curious has happened: Pharma and VC dollars started gushing into neuroscience research.

Biogen’s controversial new Alzheimer’s drug Aduhelm has been approved on the basis of removing amyloid plaque from the brain, but the new neuro-focused pharma and biotechs have much loftier aims. Significantly curbing or even curing the most notorious disorders would prove the Holy Grail for a complex system that has tied the world’s best drug developers in knots for decades.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an an­ti­body play­er fo­cused on PS­MA

Five months after Amgen CEO Bob Bradway stepped up to the M&A table and acquired Five Prime for $1.9 billion, following up with the smaller Rodeo acquisition, he’s gone back in for another biotech buyout.

This time around, Amgen is paying $900 million cash while committing up to $1.6 billion in milestones to bag the privately held Teneobio, an antibody drug developer that has expertise in developing new bispecifics and multispecifics. In addition, Amgen cited Teneobio’s “T-cell engager platform, which expands on Amgen’s existing leadership position in bispecific T-cell engagers by providing a differentiated, but complementary, approach to Amgen’s current BiTE platform.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Ryan Watts, Denali CEO

De­nali slips as a snap­shot of ear­ly da­ta rais­es some trou­bling ques­tions on its pi­o­neer­ing blood-brain bar­ri­er neu­ro work

Denali Therapeutics had drummed up considerable hype for their blood-brain barrier technology since launching over six years ago, hype that’s only intensified in the last 14 months following the publications of a pair of papers last spring and proof of concept data earlier this year. On Sunday, the South San Francisco-based biotech gave the biopharma world the next look at in-human data for its lead candidate in Hunter syndrome.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Why is On­col­o­gy Drug De­vel­op­ment Re­search Late to the Dig­i­tal Bio­mark­ers Game?

During the recent Annual ASCO Meeting, thousands of cancer researchers and clinicians from across the globe joined together virtually to present and discuss the latest findings and breakthroughs in cancer research and care. There were more than 5000+ scientific abstracts presented during this event, yet only a handful involved the use of motion-tracking wearables to collect digital measures relating to activity, sleep, mobility, functional status, and/or quality of life. Although these results were a bit disappointing, they should come as no surprise to those of us in the wearable technology field.

Art Levinson (Calico)

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug tar­gets

Seven years after striking up a major R&D alliance, AbbVie and Google-backed anti-aging specialist Calico are doubling down on their work with a joint, $1 billion commitment to continuing their work together. And they’re also beginning to offer some details on where this project is taking them in the clinic.

According to their statement, each of the two players is putting up $500 million more to keep the labs humming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Andrea Pfeifer, AC Immune CEO (AC Immune)

Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's vac­cine

The German billionaires behind BioNTech have found a new vaccine project to back.

Through their family office Athos Service, twin brothers Thomas and Andreas Strüngmann are leading a $25 million private placement into Switzerland’s AC Immune — which concurrently announced that it’s shelling out $58.7 million worth of stock to acquire Affiris’ portfolio of therapies targeting alpha-synuclein, including a vaccine candidate, for Parkinson’s disease.

Rajiv Shukla, Constellation Alpha Holdings

Can­del gets busy IPO week mov­ing with down­sized raise as Ra­jiv Shuk­la's third SPAC goes pub­lic

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

In a week that’s expected to see several biotechs price their IPOs, Candel Therapeutics got things kicked off Tuesday with a muted opener.

The company helmed by former GlaxoSmithKline vet Paul Peter Tak made its way to Nasdaq thanks to a $72 million raise, which was downsized by about 15% than originally anticipated, according to Renaissance Capital. Candel priced at $8 per share after initially seeking to launch in the $13 to $15 range.

Busi­ness­es and schools can man­date the use of Covid-19 vac­cines un­der EUAs, DOJ says

As public and private companies stare down the reality of the Delta variant, many are now requiring that their employees or students be vaccinated against Covid-19 prior to attending school or to returning or starting a new job. Claims that such mandates are illegal or cannot be used for vaccines under emergency use authorizations have now been dismissed.

Setting the record straight, the Department of Justice on Monday called the mandates legal in a new memo, even when used for people with vaccines that remain subject to EUAs.

Ugur Sahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)

BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

Flush with the success of its mRNA Covid-19 vaccine, BioNTech is now gearing up for one of the biggest challenges in vaccine development — which comes without potential profit.

The German mRNA pioneer says it plans to work on a jab for malaria, then transfer the tech to the African continent, where it will work with partners on developing the manufacturing ops needed to make this and other vaccines.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.